Nur Nicholson Sells 2,145 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Nur Nicholson sold 2,145 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $29.96, for a total transaction of $64,264.20. Following the completion of the sale, the insider now owns 52,011 shares in the company, valued at $1,558,249.56. This represents a 3.96 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Apellis Pharmaceuticals Stock Up 0.6 %

Shares of Apellis Pharmaceuticals stock traded up $0.19 on Tuesday, hitting $30.13. The company had a trading volume of 1,461,289 shares, compared to its average volume of 2,274,031. The stock has a 50-day moving average of $31.89 and a 200-day moving average of $33.31. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $71.90. The firm has a market capitalization of $3.75 billion, a P/E ratio of -14.84 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. During the same period last year, the company earned ($1.17) EPS. The company’s revenue was up 78.3% compared to the same quarter last year. Research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.71 earnings per share for the current year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in APLS. Merit Financial Group LLC acquired a new stake in Apellis Pharmaceuticals in the fourth quarter valued at $254,000. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 135.6% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 29,740 shares of the company’s stock worth $949,000 after acquiring an additional 17,115 shares during the period. Eastern Bank grew its holdings in Apellis Pharmaceuticals by 87.0% in the 4th quarter. Eastern Bank now owns 21,500 shares of the company’s stock valued at $686,000 after buying an additional 10,000 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares in the last quarter. Finally, Exome Asset Management LLC increased its holdings in shares of Apellis Pharmaceuticals by 114.0% during the third quarter. Exome Asset Management LLC now owns 100,367 shares of the company’s stock worth $2,895,000 after purchasing an additional 53,467 shares during the period. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $26.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday. William Blair began coverage on Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They issued an “outperform” rating on the stock. Morgan Stanley assumed coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday, January 14th. Finally, Mizuho lowered their price target on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday, October 24th. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).